Fact check: The standard of care for glioblastoma treatment has not changed since 2005.

Verdict: mostly true — Trust Score 82/100

The scientific claims regarding the CARv3-TEAM-E trial are confirmed by 6 sources, including the New England Journal of Medicine and the NIH. While the medical data is highly accurate, the post is framed as a marketing lead-magnet, misleadingly suggesting that social media engagement can provide 'early access' to an experimental surgical therapy.

mostly true verification card — Trust Score 82/100
Platform
instagram
Source author
drshahlongevity — see all fact-checks of this account
Original post
https://www.instagram.com/p/DX7wmvkgsJ_/?igsh=aTJ1bWI0M2ZyeTR4
Verified on
May 4, 2026
Verification ID
ZlpL2tMpzI1TqNAHj2UPfA

Original content reviewed

Platform: INSTAGRAM Author: @drshahlongevity --- Caption/Description --- Did you know glioblastoma treatment hasn’t changed since 2005? Doctors injected engineered immune cells directly into a brain tumor. Five days later, it was almost gone on MRI. Those are real scans from a real patient, published in the New England Journal of Medicine. The treatment is called CARv3-TEAM-E. It’s a next-generation CAR T cell therapy that attacks glioblastoma from two angles simultaneously, targeting EGFRvIII and wild-type EGFR. It bypasses the blood-brain barrier by being injected directly into the brain’s ventricles through a surgically placed reservoir. All three patients in this Phase 1 safety trial showed dramatic tumor regression within days of a single infusion. No serious toxic effects. Two patients saw the response fade over time. One maintained regression past day 104. Three patients is a small number and this is early data. But glioblastoma’s standard of care has not changed since 2005, and nothing has ever made this tumor respond this fast. That matters. Something big is coming. Comment “CARTCELL” to be first in line. 👇 📚 Source (PMID) PMID: 38477966 https://www.nejm.org/doi/full/10.1056/NEJMoa2314390 ⚠️ Disclaimer This content is for informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making changes to your diet or health routine. --- Carousel/Slides (7 items) --- Slide 1 (image): Text: DOCTORS INJECTED SOMETHING DIRECTLY INTO A BRAIN TUMOR. 5 DAYS LATER, IT WAS ALMOST GONE. THIS IS WHAT IT LOOKED LIKE ON THE MRI. Slide 2 (image): Text: A. Timeline of Events for Participant 1 B MRI in Participant 1 C EGFRvIII and EGFR in CSF-Derived evRNA D EGFRvIII and EGFR in Peripheral Blood-Derived evRNA THREE PATIENTS WITH RECURRENT GLIOBLASTOMA, THE DEADLIEST FORM OF BRAIN CANCER, WITH A MEDIAN SURVIVAL UNDER 15 MONTHS, RECEIVED A SINGLE INFUSION OF ENGINEER

Claims analyzed (4)

  1. mostly true: The standard of care for glioblastoma treatment has not changed since 2005.
    The 'Stupp protocol' (surgery, radiation, and temozolomide) was established in 2005 and remains the foundational standard. While Tumor-Treating Fields (Optune) was added in 2015, many experts agree no major pharmacological shift has occurred since 2005.
  2. verified: CARv3-TEAM-E is a next-generation CAR T cell therapy that targets both EGFRvIII and wild-type EGFR.
    The study confirms the therapy uses a CAR to target EGFRvIII and secretes T-cell–engaging antibody molecules (TEAMs) to target wild-type EGFR.
  3. verified: A Phase 1 safety trial of CARv3-TEAM-E involving three patients showed dramatic tumor regression within days.
    The INCIPIENT trial results published in NEJM documented rapid regression in all three initial participants, with some responses visible on MRI within 24-48 hours.
  4. verified: One patient in the CARv3-TEAM-E trial maintained tumor regression past day 104 post-infusion.
    Participant 2 in the study showed a 60.7% reduction that was sustained for over 150 days (roughly 5 months) at the time of reporting.

Sources consulted (14)

Related verifications

AI-generated analysis. Not a substitute for professional fact-checking.